





*Systematic Review*

# Response to peptide receptor radionuclide therapy in pheochromocytomas and paragangliomas: a systematic review and meta-analysis.

Supplementary



**Figure S1.** Funnel plot for response rate (complete plus partial responses) in the selected studies.



**Figure S2.** Forest plot for response rate (complete plus partial responses) in the selected articles.

**Table S1.** Pooled age and time-to-event in selected studies.

Characteristic	Articles assessed	Treatment	
		177LU-DOTATATE	90Y-DOTATOC
Patients' age (years), mean (95% CI)	Garske-Román U. <i>et al.</i>	46.42 (38.62-54.22)	Incalculable*
	Jaiswal SK. <i>et al.</i>		
	Pinato DJ. <i>et al.</i>		
	Prado-Wohlwend S. <i>et al.</i>		
	Vyakaranam AR. <i>et al.</i>		
	Zandee WT. <i>et al.</i>		
Progression-free survival (months)	Demirci E. <i>et al.</i>	24.5 ± 6.5	Incalculable*
	Garske-Román U. <i>et al.</i>		
	Jaiswal SK. <i>et al.</i>		
	Pinato DJ. <i>et al.</i>		
	Prado-Wohlwend S. <i>et al.</i>		
	Vyakaranam AR. <i>et al.</i>		
Overall survival (months)	Zandee WT. <i>et al.</i>	48.9 ± 4.7	Incalculable*
	Demirci E. <i>et al.</i>		
	Garske-Román U. <i>et al.</i>		
	Pinato DJ. <i>et al.</i>		
	Vyakaranam AR. <i>et al.</i>		

\*There were no sufficient data to draw pooled age and/or time-to-event in 90Y-DOTATATE studies.  
CI: Confidence Intervals.